119 related articles for article (PubMed ID: 31982182)
21. Upstaging of nonurothelial histology in bladder cancer at the time of surgical treatment in the National Cancer Data Base.
Cohen AJ; Packiam V; Nottingham C; Steinberg G; Smith ND; Patel S
Urol Oncol; 2017 Jan; 35(1):34.e1-34.e8. PubMed ID: 27592529
[TBL] [Abstract][Full Text] [Related]
22. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder.
Calvete J; Larrinaga G; Errarte P; Martín AM; Dotor A; Esquinas C; Nunes-Xavier CE; Pulido R; López JI; Angulo JC
Hum Pathol; 2019 Sep; 91():61-68. PubMed ID: 31279874
[TBL] [Abstract][Full Text] [Related]
23. Risk of Late Urinary Complications Following Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: Refining Bladder Dose-Volume Parameters.
Manea E; Escande A; Bockel S; Khettab M; Dumas I; Lazarescu I; Fumagalli I; Morice P; Deutsch E; Haie-Meder C; Chargari C
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):411-420. PubMed ID: 29559282
[TBL] [Abstract][Full Text] [Related]
24. Basal-subtype bladder tumours show a 'hot' immunophenotype.
Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
Histopathology; 2018 Nov; 73(5):748-757. PubMed ID: 29947424
[TBL] [Abstract][Full Text] [Related]
25. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
[TBL] [Abstract][Full Text] [Related]
26. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
27. Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy.
Hamilton SN; Tyldesley S; Hamm J; Jiang WN; Keyes M; Pickles T; Lapointe V; Kahnamelli A; McKenzie M; Miller S; Morris WJ
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):934-41. PubMed ID: 25240272
[TBL] [Abstract][Full Text] [Related]
28. Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer.
Guo X; Liu M; Hou H; Liu S; Zhang X; Zhang Y; Wu P; Pang C; Wang J
Int J Clin Oncol; 2019 Aug; 24(8):957-965. PubMed ID: 30903422
[TBL] [Abstract][Full Text] [Related]
29. Devastating complications after brachytherapy in the treatment of prostate adenocarcinoma.
Moreira SG; Seigne JD; Ordorica RC; Marcet J; Pow-Sang JM; Lockhart JL
BJU Int; 2004 Jan; 93(1):31-5. PubMed ID: 14678363
[TBL] [Abstract][Full Text] [Related]
30. Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma.
Buckstein M; Kerns S; Forysthe K; Stone NN; Stock RG
BJU Int; 2013 Mar; 111(3 Pt B):E43-7. PubMed ID: 23046084
[TBL] [Abstract][Full Text] [Related]
31. Urachal carcinomas of the nonglandular type: salient features and considerations in pathologic diagnosis.
Paner GP; Barkan GA; Mehta V; Sirintrapun SJ; Tsuzuki T; Sebo TJ; Jimenez RE
Am J Surg Pathol; 2012 Mar; 36(3):432-42. PubMed ID: 22301493
[TBL] [Abstract][Full Text] [Related]
32. [Focal dose escalation in the treatment of prostate cancer : Long-term results of HDR brachytherapy].
Cordes J; Broschk J; Sommerauer M; Jocham D; Merseburger AS; Melchert C; Kovács G
Urologe A; 2017 Feb; 56(2):157-166. PubMed ID: 27376359
[TBL] [Abstract][Full Text] [Related]
33. Three new primary pelvic carcinomas in a patient following radiotherapy for carcinoma of the cervix. Case report.
Gatzen C; Vipond MN; Fish DE; Snell ME
Acta Chir Scand; 1990 Feb; 156(2):183-6. PubMed ID: 2330800
[TBL] [Abstract][Full Text] [Related]
34. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
[TBL] [Abstract][Full Text] [Related]
35. Pathological characteristics and prognostic indicators of different histopathological types of urinary bladder cancer following radical cystectomy in a large single-center Egyptian cohort.
Martin JW; Vernez SL; Lotan Y; Abdelhalim A; Dutta R; Shokeir A; Abol-Enein H; Mosbah A; Ghoneim M; Youssef RF
World J Urol; 2018 Nov; 36(11):1835-1843. PubMed ID: 29761225
[TBL] [Abstract][Full Text] [Related]
36. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention.
Zelefsky MJ; Pei X; Teslova T; Kuk D; Magsanoc JM; Kollmeier M; Cox B; Zhang Z
BJU Int; 2012 Dec; 110(11):1696-701. PubMed ID: 22889401
[TBL] [Abstract][Full Text] [Related]
37. Prostatic sarcoma after conservative treatment with brachytherapy for low-risk prostate cancer.
Domínguez A; Piulats JM; Suárez JF; Condom E; Castells M; Camps N; García Del Muro FX; Franco E
Acta Oncol; 2013 Aug; 52(6):1215-6. PubMed ID: 23095143
[No Abstract] [Full Text] [Related]
38. Robot-assisted Laparoscopic Implantation of Brachytherapy Catheters in Bladder Cancer.
Bosschieter J; Vis AN; van der Poel HG; Moonen LM; Horenblas S; van Rhijn BWG; Pieters BR; Nieuwenhuijzen JA; Hendricksen K
Eur Urol; 2018 Sep; 74(3):369-375. PubMed ID: 28619396
[TBL] [Abstract][Full Text] [Related]
39. Prostate radiotherapy is associated with second cancers in many organs, not just the colorectum.
Brenner DJ; Hall EJ; Curtis RE; Ron E
Gastroenterology; 2005 Aug; 129(2):773-4; author reply 774-5. PubMed ID: 16083746
[No Abstract] [Full Text] [Related]
40. Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder.
Borhan WM; Cimino-Mathews AM; Montgomery EA; Epstein JI
Am J Surg Pathol; 2017 Nov; 41(11):1570-1575. PubMed ID: 28786878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
